RVTY
RevvityANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The quarter beat on revenue and adjusted EPS, diagnostics growth stayed solid, and the China divestiture could improve portfolio quality and mix. The available sell-side target set still sits above the stock, so there is room for a rerate if execution holds.
Posture
Constructive
Lead driver
Momentum
What changed
4 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Adjusted operating margin fell to 23.6% in Q1 from 25.6% a year ago, so operating leverage is not yet fully recovered [#8-K-2026-05-05].
Momentum
69
Value
63
Sentiment
55
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $111.00 · Bull $126.00 · Bear $86.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $117.88
Why
Momentum69 · Δ7d +13.1
Value63 · Δ7d +0.1
Sentiment55 · Δ7d -10.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
69
34% active weight
Current posture
7d trendImproving
Δ7d
+13.1
Δ21d
+37.5
Value
63
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.6
Sentiment
55
33% active weight
Current posture
7d trendSoftening
Δ7d
-10.5
Δ21d
-2.6
Why this grade
Composite grade A. Momentum 68.6 / Value 63.3 / Sentiment 55.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$11.21B
Beta
1.06
Shares Out
113.38M
P/E (TTM)
52.3
P/S (TTM)
4.11
P/FCF (TTM)
24.94
Rev YoY
+2.2%
EPS YoY
-46.1%
Gross Margin
+55.3%
Op Margin
+12.9%
Net Debt
$1.99B
Current Ratio
1.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology